Western District of Virginia U.S. Attorney's Office

The Western District of Virginia U.S. Attorney's Office is portrayed as a small federal office that turned years of scattered evidence into a sustained criminal investigation of Purdue Pharma. Its inquiry differed from earlier civil actions: prosecutors did not have to prove that the company’s conduct caused particular overdoses or cases of addiction, but they did have to establish criminal misbranding. The office’s persistence, its division of work between Roanoke and Abingdon, and its eventual plea agreement make it a central institutional actor in the book’s account of the effort to hold Purdue accountable.

Office and Investigative Leadership

The investigation took shape under John Brownlee, a young U.S. attorney with political ambitions who was secretly pursuing a case against Purdue as early as 2003. A former paratrooper and Army Reserve JAG Corps captain, Brownlee was thirty-six when the effort began. The book describes him as brash and comfortable with public attention: he traveled with a portable podium for press conferences and had acquired a reputation for aggressive, sometimes overreaching prosecution. His office was still smarting from an earlier trial loss in a multiple wrongful-death suit against Roanoke pain specialist Dr. Cecil Knox. That case ended in an acquittal, a hung jury, and dismissal; the raid on Knox’s practice, in which staff were handcuffed and taken away despite arrangements for them to surrender, had also drawn criticism.

Brownlee’s conspicuous public style was not the model adopted by the prosecutors who led the Purdue investigation day to day. He appointed Randy Ramseyer and Rick Mountcastle, career government lawyers based three hours west of him in the office’s Abingdon satellite, closer to the coalfields. They were described as quiet, unsentimental workers rather than performers at a podium. Their experience was grounded in the region’s cases: before the Purdue inquiry, they had sent pill-mill doctors to prison, including one who dispensed prescriptions from the back seat of his car. Since OxyContin’s introduction, their small office had successfully prosecuted ten doctors, pharmacists, and dentists for overprescribing drugs, including prescriptions to children as young as nine.

Building the Purdue Case

The investigation drew on material collected well beyond the prosecutors’ own files. When Barry Meier was temporarily kept from writing about Purdue for The New York Times after the company’s lawyer, Howard Udell, challenged his independence, Brownlee turned to the footnotes of Meier’s book. Gregg Wood, a fraud investigator in the office, helped connect the federal team with Art Van Zee and parents involved in Relatives Against Purdue Pharma. Wood had already been circulating regular email compilations of OxyContin-related news and overdose statistics to law-enforcement agents, prosecutors, and other interested readers. Van Zee nicknamed them the Wood Reports. Wood urged recipients to alert him to local coverage, and by the Purdue inquiry those updates were being issued four or five times a week.

The office also absorbed records from earlier legal battles. Fayne McCauley’s case files, including sales-representative call notes and depositions, became part of the prosecutors’ documentary resources rather than languishing in a law-office attic. By the time McCauley’s case was lost, Brownlee’s office was secretly logging millions of records in spreadsheets. One employee worked solely on cataloguing documents. Together, the files and the continuing stream of news and statistics supported Brownlee’s belief that Purdue had knowingly concealed the drug’s addictiveness. When a New York Post reporter disclosed in 2005 that a federal grand jury was investigating the company, families who had faced Purdue’s civil defenses understood the inquiry as a challenge to the company’s confidence that it could prevail against local opponents.

The effort expanded beyond the immediate office. Brownlee brought in prosecutors from neighboring jurisdictions and deputized them as special assistants so that other federal work would not go unattended. Nine state and federal agencies would ultimately spend five years helping build the case. The scale of the effort countered Purdue’s apparent assumption that a small, regional prosecution team could be brushed aside. Brownlee also prepared for settlement discussions with Rudy Giuliani, who made calls on Purdue’s behalf, by reading Giuliani’s book Leadership before their first meeting. The book depicts Giuliani’s prominence as a pressure tactic, but Brownlee’s response was to emphasize the prosecutors’ ability to prevail through preparation and persistence rather than institutional size.

Legal Strategy and Precedents

The case was shaped by the difficulty of proving that Purdue had broken the law. During the drug’s first decade, the legal system had not been able to establish that its makers had violated it. Earlier federal efforts had largely fallen short, with a few exceptions. Jay McCloskey, a U.S. attorney in Maine, had challenged Purdue’s promotional methods with some success, pressing the company to end doctor junkets and its 160-milligram pill. He later left government service to work as a consultant for Purdue, a reversal that underscored how fragile earlier efforts had been.

The Abingdon prosecutors pursued a different legal route. The charge of misbranding could cover mislabeling a drug, fraudulent promotion, or marketing for an unapproved use. For this case, prosecutors did not need to prove that Purdue’s conduct directly caused individual overdoses, addiction, or misuse. They needed to prove criminal misbranding. The legal boundary was described as technical and difficult to navigate, but Ramseyer and Mountcastle worked through it. Their approach made the case less dependent on linking corporate conduct to each person’s harm than the preceding civil lawsuits had been. The eventual plea agreement followed a four-year run-up in which prosecutors worked to establish that a crime could be found within the mass of company records.

Place in the Book’s Wider Argument

The office’s Purdue investigation sits beside a broader account of how law enforcement responded to the changing drug crisis. In Roanoke, heroin had long been regarded as an inner-city drug, and its small, largely unseen population of users was associated in local understanding with Black residents. As opioid use spread among white communities, the book describes a striking contrast: white users who dealt drugs or committed property crimes to stave off withdrawal were often discussed as people who could not be arrested out of an epidemic, while Ronnie Jones and many other Black and brown people arrested for selling drugs remained subject to punitive enforcement. The account cites racial disparities in both drug arrests and imprisonment, as well as lower opioid-prescribing rates for people of color, which helped leave their overdose-death rates comparatively unchanged while deaths among young white people rose sharply.

That contrast gives the federal prosecution a complicated place in the narrative. The office’s work against Purdue sought to establish corporate criminal responsibility for the promotion of an addictive drug; it is not presented as a complete remedy for the unequal policing and incarceration surrounding drug use and drug sales. Elsewhere, the book considers alternatives that join treatment, housing, employment support, and harm reduction, including the work of the Equal Justice Initiative in Seattle. Against those approaches, the office’s investigation represents both the possibility of sustained legal accountability for a powerful company and the limits of a drug policy that continues to treat different populations through sharply different institutions.